PL434198A1 - Związki do leczenia lub diagnostyki COVID-19 - Google Patents

Związki do leczenia lub diagnostyki COVID-19

Info

Publication number
PL434198A1
PL434198A1 PL434198A PL43419820A PL434198A1 PL 434198 A1 PL434198 A1 PL 434198A1 PL 434198 A PL434198 A PL 434198A PL 43419820 A PL43419820 A PL 43419820A PL 434198 A1 PL434198 A1 PL 434198A1
Authority
PL
Poland
Prior art keywords
covid
diagnosis
compounds
treatment
prevention
Prior art date
Application number
PL434198A
Other languages
English (en)
Inventor
Marcin Drąg
Wioletta RUT
Original Assignee
Politechnika Wrocławska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Politechnika Wrocławska filed Critical Politechnika Wrocławska
Priority to PL434198A priority Critical patent/PL434198A1/pl
Priority to EP21752770.4A priority patent/EP4161497A1/en
Priority to PCT/PL2021/050037 priority patent/WO2021246886A1/en
Publication of PL434198A1 publication Critical patent/PL434198A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Przedmiotem zgłoszenia są związki do stosowania w leczeniu, profilaktyce lub diagnostyce COVID-19.
PL434198A 2020-06-04 2020-06-04 Związki do leczenia lub diagnostyki COVID-19 PL434198A1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL434198A PL434198A1 (pl) 2020-06-04 2020-06-04 Związki do leczenia lub diagnostyki COVID-19
EP21752770.4A EP4161497A1 (en) 2020-06-04 2021-06-04 Compounds for the treatment or diagnosis of covid-19
PCT/PL2021/050037 WO2021246886A1 (en) 2020-06-04 2021-06-04 Compounds for the treatment or diagnosis of covid-19

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL434198A PL434198A1 (pl) 2020-06-04 2020-06-04 Związki do leczenia lub diagnostyki COVID-19

Publications (1)

Publication Number Publication Date
PL434198A1 true PL434198A1 (pl) 2021-12-06

Family

ID=77300961

Family Applications (1)

Application Number Title Priority Date Filing Date
PL434198A PL434198A1 (pl) 2020-06-04 2020-06-04 Związki do leczenia lub diagnostyki COVID-19

Country Status (3)

Country Link
EP (1) EP4161497A1 (pl)
PL (1) PL434198A1 (pl)
WO (1) WO2021246886A1 (pl)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL445143A1 (pl) * 2023-06-06 2024-12-09 Politechnika Wrocławska Zastosowanie peptydowej pochodnej fosfonowego analogu argininy Bt-Ile-Ser-ArgP(OPh)2 jako środka o aktywności przeciwbakteryjnej

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9597274B2 (en) * 2015-06-17 2017-03-21 Avon Products, Inc. Peptides and their use in the treatment of skin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL445143A1 (pl) * 2023-06-06 2024-12-09 Politechnika Wrocławska Zastosowanie peptydowej pochodnej fosfonowego analogu argininy Bt-Ile-Ser-ArgP(OPh)2 jako środka o aktywności przeciwbakteryjnej

Also Published As

Publication number Publication date
WO2021246886A1 (en) 2021-12-09
EP4161497A1 (en) 2023-04-12

Similar Documents

Publication Publication Date Title
MX2022000711A (es) Inhibidores de parp1.
JOP20200209A1 (ar) مثبطات cd73
MD3313423T2 (ro) Compoziții care conțin tulpini bacteriene de Blautia pentru tratamentul hipersensibilității viscerale
JOP20180039A1 (ar) مثبطات pd-1/pd-l1
CO2017006230A2 (es) Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática
MX2019014041A (es) Inhibidores pirazolicos de magl.
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
GEP20227406B (en) Chromane monobactam compounds for the treatment of bacterial infections
MX2018007266A (es) Combinaciones para el tratamiento del cancer.
EA201891644A1 (ru) Антибактериальные соединения и их применение
EA201891377A1 (ru) ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ
CO2022000214A2 (es) Composiciones para el tratamiento de la pérdida del cabello
UY38352A (es) Inhibidores de integrina alfavbeta6
MX2022000811A (es) Inhibidores de enzimas.
PH12021550122A1 (en) Solubilized apyrases, methods and use
CY1124851T1 (el) Νεες ενωσεις
MX392976B (es) Composiciones que comprenden cepas bacterianas.
TR201905392T4 (tr) Ağrı tedavisi.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX2022005358A (es) Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso.
PL434198A1 (pl) Związki do leczenia lub diagnostyki COVID-19
MX2020010338A (es) Uso de calcifediol en pacientes de cirugia bariatrica.
ZA202106519B (en) Caspase inhibitors and methods of use thereof
BR112018012126A2 (pt) ?adjuvante, método para prevenir e/ou tratar uma doença autoimune, e, uso de um adjuvante?